Medi-Caps Ltd.
26.25
INR
+1.25
(+5.00%)
ISIN
INE442D01010
Return %
Stock
S&P 500
1Y
-30.87
14.20
3Y
-38.09
81.12
5Y
-35.19
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Alok K. Garg
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 201, Pushpratna Paradise Indore MP India 452001
- IPO Date
- Jan 11, 1990
- Website
- medicaps.com
- Similar Companies
- Business
- Medi-Caps Limited operates as a flagship manufacturing company specializing in the production of empty hard gelatin capsules primarily used in the pharmaceutical industry. The company offers a diverse range of capsule products including regular empty hard gelatin capsules; specialized capsules such as flavored capsules, Halal gelatin capsules, preservative-free capsules, SLS-free capsules, and sweet capsules; liquid fill capsules designed for semi-liquid, paste, and liquid formulations; and metallic-colored Pearlz capsules. Its manufacturing facilities incorporate international-standard automatic machines and utilize high-quality gelatin sourced domestically. Medi-Caps serves a broad customer base domestically and internationally, exporting approximately 40% of its production to regions including the Far East, Middle East, South East Asia, and Africa, with ongoing efforts to expand into the European market, particularly with TSE-free gelatin capsules that meet stringent European regulatory requirements. The company maintains a robust client portfolio with multinational pharmaceutical companies. Medi-Caps was incorporated in 1986 and is headquartered in Pithampur, Madhya Pradesh, India. It is part of the Medi-Caps Group and remains listed on the Bombay Stock Exchange (BSE) under the ticker MEDICAPQ. Recent developments within the last two years indicate significant operational challenges including declining revenue and escalating losses primarily driven by a contraction in sales, with Q2 FY26 revenues reported at notably low levels compared to previous years. The company is actively addressing these challenges through cost restructuring and exploring new pharmaceutical customer contracts aimed at stabilizing and eventually restoring profitability. While no major acquisitions or partnerships have been publicly highlighted recently, strategic focus appears directed at operational resilience and market share expansion through product innovation and geographic market penetration. Medi-Caps operates mainly in the pharmaceutical excipients segment, supplying empty gelatin capsules to pharmaceutical manufacturers worldwide. Its operational footprint extends through domestic markets in India and international markets with expanding presence in Europe. The company’s specialization in multiple capsule types, adherence to regulatory standards, and manufacturing modernization efforts position it as a specialized supplier in this niche industry sector. Its extensive quality control infrastructure supports compliance with global health and safety standards, reinforcing its reputation amid competitive dynamics in pharmaceutical capsule manufacturing.